FDA’s OPQ Chief Tells Generic Drug Makers Its Time To Up Their Quality Game
Executive Summary
The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.
You may also be interested in...
The FDA Builds On Lessons Learned In Rebuilding Quality Metrics Program
US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.
Drug Review Reorganization At US FDA Coming Into Focus
Oncology, neuroscience, and infectious diseases get acting directors as the expansion and renovation of the Office of New Drugs moves into Phase II.
Drug Shortage Plan Would Grade Firms To Encourage High-Quality Production
US FDA task force recommends a rating system that purchasers could rely on to reward manufacturers with robust management systems.